NEW YORK (GenomeWeb) – Abbott today said that its Diagnostics business grew sales 5 percent year over year in the third quarter, driven in part by strong growth in its core laboratory and point-of-care tests.

For the three months ended September 30, Abbott reported overall revenues of $6.83 billion, up 29 percent on a reported basis and up 6 percent on a comparable operational basis from $5.30 billion in Q3 2016. The company beat the consensus Wall Street estimate of $6.72 billion.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.